title: Peroxisome proliferator-activated receptor-γ ameliorates pulmonary arterial hypertension by inhibiting 5-hydroxytryptamine 2B receptor.
abstract: An elevated plasma level of 5-hydroxytryptamine (5-HT) or upregulation of 5-HT receptor signaling or both is implicated in vascular contraction and remodeling in pulmonary arterial hypertension (PAH). Recently, peroxisome proliferator-activated receptor-γ (PPARγ) agonists have been shown to ameliorate PAH. However, their effects on the 5-HT-induced contraction of pulmonary arteries remain unknown. Here, we examined the role of PPARγ in inhibiting 5-HT2B receptor (5-HT2BR) to ameliorate PAH. Pulmonary arteries from PAH rats induced by monocrotaline or chronic hypoxia showed an enhanced vasoconstriction in response to BW723C86, a specific agonist for 5-HT2BR. Expression of 5-HT2BR was also increased in pulmonary arteries from the PAH rats, accompanied by vascular remodeling and right ventricular hypertrophy. Treatment with the PPARγ agonist rosiglitazone in vivo reversed the expression and the vasocontractive effect of 5-HT2BR as well as the thickening of pulmonary arteries. In pulmonary artery smooth muscle cells, 5-HT induced the gene expression of 5-HT2BR, which was inhibited by rosiglitazone, pioglitazone, or adenovirus-mediated overexpression of constitutively activated PPARγ. The pharmacological effect of PPARγ was through the suppression of the 5-HT-induced activator protein-1 activity. These results demonstrated the beneficial effect of PPARγ on 5-HT2BR-mediated vasocontraction, providing a new mechanism for the potential use of PPARγ agonists in PAH.
authors.affiliation: Institute of Cardiovascular Science, Peking University, Beijing 100191, China.
authors.forename: Yahan
authors.initials: Y
authors.lastname: Liu
authors.forename: Xiao Yu
authors.initials: XY
authors.lastname: Tian
authors.forename: Guangmei
authors.initials: G
authors.lastname: Mao
authors.forename: Xi
authors.initials: X
authors.lastname: Fang
authors.forename: Man Lung
authors.initials: ML
authors.lastname: Fung
authors.forename: John Y-J
authors.initials: JY
authors.lastname: Shyy
authors.forename: Yu
authors.initials: Y
authors.lastname: Huang
authors.forename: Nanping
authors.initials: N
authors.lastname: Wang
mesh_terms: D000818:Animals; D065627:Familial Primary Pulmonary Hypertension; D006976:Hypertension, Pulmonary / Q000209:etiology / Q000378:metabolism* / Q000503:physiopathology; D000860:Hypoxia / Q000150:complications / Q000378:metabolism / Q000503:physiopathology; D007211:Indoles / Q000494:pharmacology; D016686:Monocrotaline; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D032389:Myocytes, Smooth Muscle / Q000187:drug effects / Q000378:metabolism; D047495:PPAR gamma / Q000819:agonists / Q000378:metabolism*; D011651:Pulmonary Artery / Q000187:drug effects / Q000378:metabolism* / Q000503:physiopathology; D044403:Receptor, Serotonin, 5-HT2B / Q000378:metabolism*; D000077154:Rosiglitazone; D058826:Serotonin 5-HT2 Receptor Agonists / Q000494:pharmacology; D045162:Thiazolidinediones / Q000494:pharmacology; D013876:Thiophenes / Q000494:pharmacology; D018808:Transcription Factor AP-1 / Q000378:metabolism; D015854:Up-Regulation
chemical_list: C092430:1-(5-(2-thenyloxy)-1H-indol-3-yl)propan-2-amine; D007211:Indoles; D047495:PPAR gamma; D044403:Receptor, Serotonin, 5-HT2B; D058826:Serotonin 5-HT2 Receptor Agonists; D045162:Thiazolidinediones; D013876:Thiophenes; D018808:Transcription Factor AP-1; D000077154:Rosiglitazone; D016686:Monocrotaline